<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0217513</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1037</journal-id>
<journal-id journal-id-type="nlm-ta">Biochim Biophys Acta</journal-id>
<journal-id journal-id-type="iso-abbrev">Biochim. Biophys. Acta</journal-id>
<journal-title-group>
<journal-title>Biochimica et biophysica acta</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3002</issn>
<issn pub-type="epub">1878-2434</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27713004</article-id>
<article-id pub-id-type="pmc">5360178</article-id>
<article-id pub-id-type="doi">10.1016/j.bbalip.2016.09.022</article-id>
<article-id pub-id-type="manuscript">NIHMS823601</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Biological and pathophysiological roles of end-products of DHA oxidation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Yakubenko</surname>
<given-names>Valentin P.</given-names>
</name>
<xref ref-type="aff" rid="A1">*</xref>
<xref ref-type="aff" rid="A2">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Byzova</surname>
<given-names>Tatiana V.</given-names>
</name>
<xref ref-type="aff" rid="A1">*</xref>
<xref ref-type="corresp" rid="CR1">±</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>*</label>Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH</aff>
<aff id="A2"><label>#</label>Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN.</aff>
<author-notes>
<corresp id="CR1"><label>±</label>Correspondence to Dr. Tatiana Byzova, Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Mail Code NB50,9500 Euclid Avenue, Cleveland, OH 44195, <email>byzovat@ccf.org</email>, phone: (216)-445-4312</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>5</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>03</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2018</year>
</pub-date>
<volume>1862</volume>
<issue>4</issue>
<fpage>407</fpage>
<lpage>415</lpage>
<!--elocation-id from pubmed: 10.1016/j.bbalip.2016.09.022-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Polyunsaturated fatty acids (PUFA) are known to be present and/or enriched in vegetable and fish oils. Among fatty acids, n-3 PUFA are generally considered to be protective in inflammation-related diseases. The guidelines for substituting saturated fatty acids for PUFAs have been highly publicized for decades by numerous health organizations. Recently, however, the beneficial properties of n-3 PUFA are questioned by detailed analyses of multiple randomized controlled clinical trials. The reported heterogeneity of results is likely due not only to differential effects of PUFAs on various pathological processes in humans, but also to the wide spectrum of PUFA's derived products generated <italic>in vivo</italic>.</p>
</sec>
<sec id="S2">
<title>Scope of review</title>
<p id="P2">The goal of this review is to discuss the studies focused on well-defined end-products of PUFAs oxidation, their generation, presence in various pathological and physiological conditions, their biological activities and known receptors. Carboxyethylpyrrole (CEP), a DHA-derived oxidized product, is especially emphasized due to recent data demonstrating its pathophysiological significance in many inflammation-associated diseases, including atherosclerosis, hyperlipidemia, thrombosis, macular degeneration, and tumor progression.</p>
</sec>
<sec id="S3">
<title>Major conclusions</title>
<p id="P3">CEP is a product of radical-based oxidation of PUFA that forms adducts with proteins and lipids in blood and tissues, generating new powerful ligands for TLRs and scavenger receptors. The interaction of CEP with these receptors affects inflammatory response, angiogenesis, and wound healing.</p>
</sec>
<sec id="S4">
<title>General Significance</title>
<p id="P4">The detailed understanding of CEP–mediated cellular responses may provide a basis for the development of novel therapeutic strategies and dietary recommendations.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Polyunsaturated fatty acids</kwd>
<kwd>carboxyethylpyrrole</kwd>
<kwd>docosahexaenoic acid</kwd>
<kwd>inflammation</kwd>
<kwd>toll-like receptors</kwd>
<kwd>CD36</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>